Coleen Glessner - Dec 9, 2022 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Stock symbol
EBS
Transactions as of
Dec 9, 2022
Transactions value $
$0
Form type
4
Date filed
12/13/2022, 04:20 PM
Previous filing
Apr 12, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Award $0 +24.1K +203.6% $0.00 35.9K Dec 9, 2022 Direct F1
transaction EBS Common Stock Award $0 +72.2K +201.18% $0.00 108K Dec 9, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F2 Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the day prior to the second anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.